Alnylam (ALNY) director Stuart Arbuckle reports zero beneficial ownership on Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Alnylam Pharmaceuticals, Inc. director Stuart A. Arbuckle filed an initial insider ownership report. This Form 3 indicates that, as of the event date of 01/05/2026, he holds no securities beneficially owned in Alnylam. The filing confirms his role as a director and that the report is filed by one reporting person.
The document also includes a power of attorney, under which Brett Budzinski signed on Arbuckle's behalf. This filing is primarily administrative, establishing Arbuckle’s status as an insider without disclosing any equity ownership or transactions.
Positive
- None.
Negative
- None.
FAQ
What does the latest Form 3 filing reveal about ALNY director Stuart A. Arbuckle?
The Form 3 shows that director Stuart A. Arbuckle has no securities beneficially owned in Alnylam Pharmaceuticals, Inc. (ALNY) as of 01/05/2026.
What is the relationship of Stuart A. Arbuckle to Alnylam Pharmaceuticals (ALNY)?
Stuart A. Arbuckle is reported as a director of Alnylam Pharmaceuticals, Inc. (ALNY) and is not listed as an officer or 10% owner in this Form 3.
Who signed the Form 3 for Alnylam (ALNY) director Stuart A. Arbuckle?
The Form 3 is signed "By: Brett Budzinski, Attorney-in-Fact For: Stuart A. Arbuckle", indicating it was executed under a power of attorney.
Does this Alnylam (ALNY) Form 3 disclose any insider transactions?
No transactions are disclosed. The Form 3 serves only as an initial statement of beneficial ownership, which is reported as zero.